Keywords: irAE; immune related adverse event; ECOG PS; European cooperative oncology group performance status; n.s.; not significant; EGFR; epidermal growth factor receptor; ALK; anaplastic lymphoma kinase; PD-L1; programmed death-ligand 1; TKI; tyrosine-kinase inh
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: CSF; cerebrospinal fluid; GAD; glutamic acid decarboxylase; ICI; immune checkpoint inhibitor; irAE; immune-related adverse effect; MRI; magnetic resonance imaging; PCD; paraneoplastic cerebellar degeneration; PD-1; programmed death-1;
Keywords: biomarker; cancer outcome; cutaneous adverse event; cutaneous toxicity; oncodermatology; prognostic marker; survival; HFS; hand foot syndrome; HFSR; hand-foot skin reaction; HR; hazard ratio; irAE; immune-related adverse effect; NSCLC; non-small cell
Keywords: HNSCC; head and neck squamous cell carcinoma; R/M; recurrent and/or metastatic; ICPi; immune checkpoint inhibitor; irAE; immune-related adverse event; Gy; gray; MRC; Medical Research Council; CK; creatinine kinase; U/L; units per Liter; AST; aspartate tra
Keywords: ICI; immune checkpoint inhibition; irAE; immune related adverse event; TME; tumor microenvironment; Melanoma; Biomarker; Checkpoint inhibitor; PD-1; CTLA-4;
Keywords: NSCLC; non-small cell lung cancer; irAE; immune-related adverse events; IIP; idiopathic interstitial pneumonia; UIP; usual interstitial pneumonia; PD-1; programmed cell death 1; ILD; interstitial lung disease; AE-IIP; acute exacerbation of idiopathic inte
Keywords: CTLA-4; cytotoxic T-lymphocyte-associated protein 4; ICI; immune checkpoint inhibitor; irAE; immune-related adverse event; mRSS; modified Rodnan skin score; PD-1; programmed cell death 1; PD-L1; programmed cell death ligand 1; RNAP3; RNA polymerase III;
Keywords: IC; immune checkpoint; ICB; immune checkpoint blocker; irAE; immune-related adverse event; NSCLC; non-small cell lung cancer; ORR; overall response rate; OS; overall survival; RCC; renal cell carcinoma; Neoplasms; Aged; Toxicity; Immunotherapy; Medical on
Keywords: cancer therapy; chemotherapy; cutaneous reactions; drug hypersensitivity; rash; target drugs; EGFR; epidermal growth factor receptor; EGFRI; epidermal growth factor receptor inhibitor; HFSR; hand-foot skin reaction; IRAE; immune-related adverse event; M
Keywords: %FVC; percent predicted forced vital capacity; 6MWT; six-minute walk test; Ab +; antibody positive; Ab â; antibody negative; AEs; adverse events; CSA; conformation-specific antibody assay; ELISA; enzyme-linked immunosorbent assay; FVC; forced vital ca
Severe interstitial pneumonia associated with anti-PD-1 immune checkpoint antibody after talc slurry pleurodesis
Keywords: SqCC; squamous cell carcinoma; anti-PD-1; anti-programmed death-1; irAE; immune-related adverse event; PS; Eastern Cooperative Oncology Group performance status; CRP; C-reactive protein; LDH; lactate dehydrogenase; CT; computed tomography; VC; vital capac
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study
Keywords: AE; adverse event; ALK; anaplastic lymphoma kinase; CR; complete response; DCR; disease control rate; ECOG PS; Eastern Cooperative Oncology Group Performance Status; EGFR; epidermal growth factor receptor; HR; hazard ratio; irAE; immune related adverse ev
Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer
Keywords: NSCLC; non-small cell lung cancer; IrAE; immune-related adverse event; PFS; progression-free survival; OS; overall survival; CMI; Charlson's comorbidity index; ECOG; Eastern Cooperative Oncology Group; ADR; adverse drug reaction; SAE; serious adverse even
Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy
Keywords: Binimetinib (PubChem CID: 10288191); Cobimetinib (PubChem CID: 16222096); Dabrafenib (PubChem CID: 44462760); Encorafenib (PubChem CID: 50922675); Trametinib (PubChem CID: 11707110); Vemurafenib (PubChem CID: 42611257); ATC; adoptively transferred T cells
Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission
Keywords: Immune-checkpoint inhibitors; Polymyositis; Immunological memory; Molecular mimicry; HBV; hepatitis B virus; ICI; immune checkpoint inhibitor; ICIM; immune checkpoint inhibitor-induced myopathy; IIM; idiopathic inflammatory myopathy; IRAE; immune-related
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer
Keywords: AE; Adverse Event; α-MSH; alpha-Melanocyte Stimulating Hormone; ADC; Antibody-Drug Conjugate; ASPS; Alveolar Soft Part Sarcoma; ASPSCR1; Alveolar Soft Part Sarcoma Chromosome Region Candidate 1; BMP-2; Bone Morphogenetic Protein-2; BRK; Breast Tumor Kina
Ipilimumab in patients with cancer and the management of dermatologic adverse events
Keywords: adverse event management; dermatologic; immune-related; ipilimumab; melanoma; pruritus; rash; vitiligo; AE; adverse event; CTLA; cytotoxic T-lymphocyte antigen; GI; gastrointestinal; irAE; immune-related adverse event;
The risk of rash associated with ipilimumab in patients with cancer: A systematic review of the literature and meta-analysis
Keywords: adverse event; cancer; drug reaction; ipilimumab; melanoma; rash; AE; adverse events; ASCO; American Society of Clinical Oncology; CI; confidence interval; CTLA-4; cytotoxic T-lymphocyte-associated antigen 4; FDA; Food and Drug Administration; IL; inter